Bladder Cancer Clinical Trial

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications

Summary

BBI-355 is an orally available, potent, and selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.

View Full Description

Full Description

BBI-355 is administered orally in various dosing schedules to subjects with locally advanced or metastatic non-resectable solid tumors harboring oncogene amplifications, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Locally advanced or metastatic non-resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists,
Single agent arm: Evidence of oncogene amplification,
BBI-355 combination with erlotinib arm: Evidence of amplification of wildtype EGFR,
BBI-355 combination with futibatinib arm: Evidence of amplification of wildtype FGFR1, FGFR2, FGFR3, or FGFR4,
Availability of FFPE tumor tissue, archival or newly obtained,
Measurable disease as defined by RECIST Version 1.1,
Adequate hematologic function,
Adequate hepatic and renal function,
Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1,
Other inclusion criteria per study protocol.

Key Exclusion Criteria:

Well-known tumor activating oncogene mutations or fusions,
Prior exposure to CHK1 inhibitors,
BBI-355 combination with erlotinib arm: Prior exposure to EGFR inhibitors,
BBI-355 combination with futibatinib arm: Prior exposure to FGFR inhibitors,
Hematologic malignancies,
Primary CNS malignancy, leptomeningeal disease, or symptomatic active CNS metastases, with exceptions per study protocol,
Prior or concurrent malignancies, with exceptions per study protocol,
History of HBV, HCV, or HIV infection,
Clinically significant cardiac condition,
Active or history of interstitial lung disease (ILD) or pneumonitis, or history of ILD or pneumonitis requiring steroids or other immunosuppressive medications,
QTcF > 470 msec,
Prior organ allograft transplantations or allogeneic peripheral blood stem cell/bone marrow transplantation,
Other exclusion criteria per study protocol.

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

150

Study ID:

NCT05827614

Recruitment Status:

Recruiting

Sponsor:

Boundless Bio

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Sarcoma Oncology
Santa Monica California, 90403, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
START Midwest
Grand Rapids Michigan, 49546, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
MD Anderson Cancer Center
Houston Texas, 77054, United States
NEXT Oncology
San Antonio Texas, 78229, United States
NEXT Oncology
Fairfax Virginia, 22031, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

150

Study ID:

NCT05827614

Recruitment Status:

Recruiting

Sponsor:


Boundless Bio

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.